Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Cash Flow (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Net Cash Flow for 12 consecutive years, with -$7.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 148.32% to -$7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $130.0 million through Dec 2025, up 7537.59% year-over-year, with the annual reading at $130.0 million for FY2025, 7537.59% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$7.0 million at Theravance Biopharma, up from -$107.2 million in the prior quarter.
  • The five-year high for Net Cash Flow was $1.1 billion in Q4 2022, with the low at -$744.1 million in Q3 2022.
  • Average Net Cash Flow over 5 years is $12.1 million, with a median of -$7.2 million recorded in 2024.
  • The sharpest move saw Net Cash Flow soared 3423.35% in 2022, then plummeted 3014.21% in 2023.
  • Over 5 years, Net Cash Flow stood at -$34.3 million in 2021, then skyrocketed by 3423.35% to $1.1 billion in 2022, then plummeted by 102.82% to -$32.1 million in 2023, then surged by 144.86% to $14.4 million in 2024, then plummeted by 148.32% to -$7.0 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$7.0 million, -$107.2 million, and $171.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.